Pricing Log in Create free account
Friday 6 November 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

IBRX Healthcare Biotechnology

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.

Revenue
+93.9%
EPS
−120.0%
Free cash flow
+13.4%
Total debt
+57.4%

Quarter to June 2026, against a year earlier

8.55 0.54 +6.74%
Market cap
$8.5B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
4/9
Altman Z
−10.16
Beneish M
4.57
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

ImmunityBio, Inc. 10-K filed Feb 23, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:24 PM ET · Document on sec.gov · Filing index

Red flags

  • Auditor change

    ImmunityBio, Inc. changed auditor from Ernst & Young LLP to Deloitte & Touche LLP

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Mar 3, 2025: 260 added · 132 removed · 96 modified; 8 with only figures updated

  1. Removed · Forward-Looking Statements

    •our ability to successfully commercialize ANKTIVA;